Human CSTB blocking peptide

Mitigation measures against railway vibration in buildings consist of elastomeric mounts or springs inserted between building foundations and upper-structures. This paper aims at predicting and checking on site the field performances of such mitigation measures expressed as a power flow insertion gain. The predicted performance is estimated from the mobilities of the isolation mounts (given by the manufacturer) and the mobilities of the supporting building structures, obtained either from measurements or from calculation using a ground structure vibration model (CSTB MEFISSTO software). The "on site" performance is estimated from velocity measurements on both sides of the isolator. Both compressional and shear wave transmissions into building are discussed. The approach is numerically validated in the simple case of a 2D building on homogeneous ground excited by any surface activity and its limits are identified.

Purpose: We report on genetic analysis of a complex condition in a Serbian family of four siblings, wherein two had progressive myoclonic epilepsy (PME) and congenital deafness (CD), one had isolated congenital deafness (ICD), and one was healthy. Methods and Results: Molecular diagnosis performed by Southern blotting confirmed Unverricht-Lundborg disease in the available sibling with PME/CD. In the sibling with ICD (heterozygote for expansion mutation in CSTB) we demonstrated recombination event between the D21S2040 marker and the CSTB gene and identified c. 207delC (p. T70Xfs) mutation in the fourth exon of the transmembrane protease, serine-3 (TMPRSS3) gene (maps in close proximity to CSTB), responsible for nonsyndromic deafness in the sibling with PME/CD as well. Discussion: To the best of our knowledge this is the first genetic confirmation of the coexistence of these two mutations.